Please enter the email address you used to register, then we will send you a link to choose a new password
JMP Securities analyst Silvan Tuerkcan downgrades Notable Labs (NASDAQ:NTBL) from Market Outperform to Market Perform.
Chardan Capital analyst Keay Nakae maintains Notable Labs (NASDAQ:NTBL) with a Buy and lowers the price target from $7 to $5.
JMP Securities analyst Silvan Tuerkcan reiterates Notable Labs (NASDAQ:NTBL) with a Market Outperform and maintains $9 price...
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...
Chardan Capital analyst Keay Nakae maintains Notable Labs (NASDAQ:NTBL) with a Buy and lowers the price target from $9 to $7.
The company presented the design for the PPMP-enabled Phase 2 trial with volasertib, in combination with decitabine, in patient...
Notable Labs, Ltd. (NASDAQ:NTBL) ("Notable" or the "Company"), a clinical-stage precision oncology company deve...
Predictive Precision Medicine Platform (PPMP) utilized to enrich program for clinically responding patients and reduce the risk...
Shares of Juniper Networks, Inc. (NYSE: JNPR) rose sharply in pre-market trading on Tuesday.